Agenus Inc. (NASDAQ:AGEN) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 10,288,366 shares, a growth of 21.5% from the October 13th total of 8,464,979 shares. Currently, 13.4% of the company’s shares are short sold. Based on an average daily volume of 3,255,541 shares, the days-to-cover ratio is currently 3.2 days.
In related news, CEO Garo H. Armen purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $3.55 per share, with a total value of $355,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 7.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. OxFORD Asset Management LLP acquired a new stake in Agenus during the 2nd quarter worth about $141,000. Voya Investment Management LLC boosted its position in Agenus by 18.5% during the 2nd quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock worth $160,000 after acquiring an additional 6,381 shares during the period. American International Group Inc. boosted its position in Agenus by 7.1% during the 1st quarter. American International Group Inc. now owns 45,013 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,984 shares during the period. UBS Asset Management Americas Inc. boosted its position in Agenus by 203.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 51,933 shares of the biotechnology company’s stock worth $196,000 after acquiring an additional 34,833 shares during the period. Finally, State of Wisconsin Investment Board acquired a new stake in Agenus during the 2nd quarter worth about $207,000. Hedge funds and other institutional investors own 39.46% of the company’s stock.
Shares of Agenus (AGEN) opened at $3.73 on Tuesday. Agenus has a 1 year low of $3.20 and a 1 year high of $5.91. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39.
Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.37). The business had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The business’s revenue was down 24.4% on a year-over-year basis. equities research analysts anticipate that Agenus will post -1.19 earnings per share for the current fiscal year.
AGEN has been the topic of a number of analyst reports. Zacks Investment Research raised Agenus from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research note on Wednesday, October 25th. ValuEngine raised Agenus from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. BidaskClub raised Agenus from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target on shares of Agenus in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $5.81.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/11/14/agenus-inc-agen-short-interest-up-21-5-in-october.html.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.